Elegen

Innovation Is Our DNA

United States · Founded 2017 · $37.0M raised

Employees
11–50
Founded
2017
Total Funding
$37.0M
Last Round
$35.0M Series BMay 2024
Rounds
2

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Elegen is a synthetic biology company that has developed ENFINIA™, the world's only entirely cell-free platform for rapid, high-quality DNA production. Using patented microfluidic synthesis, AI, and robotics, Elegen delivers long, clonal-quality, high-complexity DNA — including linear, plasmid, and IVT-ready formats — in 6 to 8 business days with 99.999% per-base accuracy. Unlike traditional approaches that require bacterial cloning and colony screening, Elegen's cell-free process eliminates bioburden, recombination, and foundry dependencies. ENFINIA DNA serves applications in cell and gene therapy, mRNA vaccines, personalized cancer vaccines, and protein expression, enabling faster and more reliable development of next-generation biologics.

Summary

Elegen is a Healthcare company based in United States, founded in 2017. It has raised $37.0M in total across 2 rounds, most recently a $35.0M Series B round in May 2024. Investors include Triatomic Capital and Andreessen Horowitz.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series BSeries BMay 2024
$35.0M

Sign up to see all 2 events

Funding: Grant through Series B. Amounts, valuations, and investors where available.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Elegen on Indexed.vc
<a href="https://indexed.vc/companies/elegen"><img src="https://indexed.vc/api/badge/company/elegen" alt="Elegen on Indexed.vc" width="260" height="76" /></a>